Xofluza is a single-dose oral medicine with a novel proposed mechanism of action that has demonstrated efficacy against a wide range of influenza viruses, including in vitro and in vivo activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies. Xofluza is the first in a class of antivirals designed to inhibit the cap-dependent endonuclease protein, which is essential for viral replication.
Xofluza is approved in the US for the treatment of acute uncomplicated influenza and patients at high risk of developing influenza complications. Xofluza is approved in more than 80 countries for the treatment of uncomplicated influenza types A and B including Japan, Switzerland, Canada, Australia and South Korea.
Xofluza was discovered by Shionogi & Co., Ltd. and is being further developed and commercialised globally in collaboration with the Roche Group (which includes Genentech in the US). Under the terms of this agreement, Roche holds worldwide rights to Xofluza excluding Japan and Taiwan, where rights will be retained exclusively by Shionogi & Co., Ltd.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.